Cargando…
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Background: Hypoglycemia rates usually increase when insulin treatment is intensified to improve glycemic control. We evaluated (post hoc) hypoglycemic rates in adult patients with type 1 diabetes (T1D) on sotagliflozin (a dual sodium-glucose cotransporter [SGLT] 1 and 2 inhibitor) in two phase 3, 5...
Autores principales: | Danne, Thomas, Pettus, Jeremy, Giaccari, Andrea, Cariou, Bertrand, Rodbard, Helena, Weinzimer, Stuart A., Bonnemaire, Mireille, Sawhney, Sangeeta, Stewart, John, Wang, Stella, Castro, Rita de Cassia, Garg, Satish K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708262/ https://www.ncbi.nlm.nih.gov/pubmed/31335194 http://dx.doi.org/10.1089/dia.2019.0157 |
Ejemplares similares
-
Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2
por: Rodbard, Helena W, et al.
Publicado: (2021) -
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
por: Peters, Anne L., et al.
Publicado: (2020) -
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
por: Baker, Claire, et al.
Publicado: (2019) -
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019) -
Trends in HbA(1c) thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients
por: Ambrož, Martina, et al.
Publicado: (2020)